Introduction {#s1}
============

The term "sarcoma" identifies a heterogeneous group of rare tumors comprising over 60 different histologic variants ([@B1]). Due to their rarity and heterogeneity, the accuracy of sarcoma diagnosis remains challenging. In the diagnosis of sarcomas, tumor cell morphology (shape, pattern of growth, microenvironment contexture) and the expression of differentiation markers represent the most important factors, but molecular investigations are increasingly employed to complement these pathological assessments. Indeed, the identification of histotype-specific (pathognomonic) gene alterations is of paramount importance in the differential diagnosis among sarcoma variants, between malignant and benign mimics, as well as between sarcoma and other tumor types ([@B1]--[@B3]). In particular, about one third of all sarcomas presents pathognomonic chromosome rearrangements (translocations, deletions, insertions) that result in fusion genes and corresponding expression of fusion transcripts ([@B4]). Beside diagnostic relevance, the expression of fusion transcripts may have prognostic and/or predictive implications. For example, certain rearrangements, such as those involving *ALK* in inflammatory myofibroblastic tumors or *COL1A1-PDGFB* in dermatofibrosarcoma protuberans, are predictive of the response to tyrosine kinase inhibitors ([@B5], [@B6]). Moreover, the detection of NTRK fusions in a broad range of malignancies, including sarcomas, has gaining much attention due to the recent demonstration of therapeutic efficacy of a new class of tyrosine kinase inhibitors in NTRK rearranged tumors ([@B7]--[@B9]).

Commonly, FISH or RT-PCR are used to detect fusion events at the genomic or transcriptional level, respectively. However, both methods present limitations. In particular, since they are suited to investigate a specific pre-defined abnormality, they inevitably rely on a prior diagnostic hypothesis (reflex testing). The advent of technologies such as next generation sequencing (NGS), aka massive parallel sequencing, has laid down the bases to overcome this limitation. By allowing the simultaneous analysis of a large set of targets (from few genes to the whole transcriptome/genome) NGS has disclosed the possibility not only to reveal diagnostic/prognostic/predictive genetic abnormalities in the absence of a prior hypothesis but also to identify new aberrations ([@B10]--[@B12]).

Here we wanted to assess feasibility, reliability, and applicability of NGS-based methods for the detection of sarcoma-associated fusion transcripts in a routine diagnostic setting. Our multicentric analysis confirms the sensitivity of anchored-based NGS profiling approaches and corroborates the suitability of these investigations in the diagnostic setting of sarcomas.

Materials and Methods {#s2}
=====================

Case Selection
--------------

The study was conducted on a series of 150 sarcoma samples, representative of different sarcoma histotypes, retrieved from the pathological files of the participating institutions (Alleanza Contro il Cancro, ACC, Italian Research Network). Either Formalin-Fixed Paraffin-Embedded (FFPE) or frozen samples were analyzed. All sarcomas included in the study were histopathologically re-evaluated on hematoxylin-eosin stained slides, and representative areas were selected for molecular analyses.

NGS-based Fusion Transcript Identification
------------------------------------------

RNA was extracted from 5 to 10 μm-FFPE tissue sections using the Qiagen miRNeasy FFPE kit (Qiagen, Valencia, CA, USA) or the Invitrogen RecoverAll Total Nucleic Acid Isolation kit (Thermo Fisher Scientific, Waltham, MA, USA). For frozen samples the TRIzol reagent (Life Technologies Italia, Monza, Italy) followed by the RNeasy MinElute cleanup (Qiagen, Valencia, CA, USA) was used. Total RNA was quantified by using a Qubit fluorometer (Thermo Fisher Scientific, Waltham, MA, USA). Quality was checked with the RNA 6000 Nano Kit on a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA), or by using the Archer PreSeq^TM^ RNA QC qPCR Assay (ArcherDX, Boulder, CO, USA) and a threshold of DV~200~ \>30 or PreSeq Cq \<31 was used to identify high quality RNA, respectively.

FISH, RT-PCR, RT-qPCR, and IHC, used as primary detection approaches for the detection of possible fusion events, were performed during routine diagnostic procedures according to laboratory standard guidelines and validated reagents.

Three different commercially available NGS-based fusion panels were selected based on their capacity to cover most genes known to be involved in sarcoma-relevant fusions: an anchored multiplex PCR-based assay, namely the Archer FusionPlex Sarcoma kit (AMP-FPS)(ArcherDX, Boulder, CO, USA), covering 26 genes involved in sarcoma-associated fusions; two hybrid capture-based (HC) assays, namely the TruSight RNA Fusion Panel (TS-Fusion) (Illumina Inc., San Diego, CA, USA) and the TruSight RNA PanCancer Panel (TS-PanCancer) (Illumina Inc., San Diego, CA, USA) covering 507 and 1,385 genes commonly involved in cancer, respectively. Both HC assays included the 26 genes covered by the AMP-FPS kit. In a subset of samples, a customized version of the AMP-FPS panel was used to detect PAX3 fusion transcripts. Specifically, the assay was integrated with PAX3-specific primers (exons 6, 7 and 8) designed by using the Archer Assay Designer tool (ArcherDX, Boulder, CO, USA).

Libraries for all three panels were prepared and checked for quality according to the manufacturer\'s instructions, starting from 100 to 250 ng of RNA as input.

AMP-FPS libraries were run on either Illumina (MiSeq or NextSeq 500 Illumina Inc., San Diego, CA, USA) or Thermo (Ion S5 Thermo Fisher Scientific, Waltham, MA, USA) sequencing platforms, according to the manufacturer\'s instructions. HC-based libraries were sequenced on Illumina MiSeq instruments. Illumina TS-Fusion and TS-PanCancer sequencing data were analyzed by using the dedicated Illumina BaseSpace RNA-Seq Alignment tool (v.s.2.0.2), which relies on STAR and Manta algorithms ([@B13], [@B14]). PAR-masked/(RefSeq)hg19 was used as reference genome. A minimum of 3 million reads was obtained per sample (range 3007307--6284475). The mean percentage of reads aligned to the human genome was 98.9% (range 96.4--99.7%); the mean proportion of reads aligned to ribosomal RNA was below 2% (range 0.2--6.1%) and mean insert size was 134 bp (range 107--155 bp), in line with literature data ([@B15]). Only high-confidence fusions that passed default thresholds of the RNA-Seq Alignment tool (PASS) were recorded.

The Archer Analysis suite (v 5.1 or v 6.0) was exploited for the analysis of AMP-FPS panel results, using default settings. Default parameters (QC PASS) that, according to the Archer user manual, allow to achieve up to 95% of sensitivity in fusion detection, were employed to assess data quality. Samples included in the study met the quality cutoffs set by the Archer Analysis platform but in a few cases that, although not fulfilling all default criteria, nevertheless yielded high confidence fusion calls (cases \#9, 31, 37, 47, 57, 60, 80, 126). Fusions were recorded as "high confidence calls"(strong = true in output table) if they passed all "strong evidence" default filters as described in the Archer analysis user manual (briefly: breakpoint spanning reads that support the candidate ≥ 5; "fusion_percent_of_GSP2_reads", i.e., proportion of breakpoint spanning reads that support the candidate relative to the total number of reads spanning the breakpoint ≥10%; "min_unique_start_sites_for_strong_fusion" ≥3; fusion recorded in the Quiver database or not fulfilling the "negative evidence criteria").

Of 48 cases (12 of the first set and 36 of the second set) where a fusion was detected by NGS but the partner genes had not been previously determined by the primary detection method, material was available for orthogonal validations (RT-PCR) in 39 cases, confirming NGS results. The involvement of *SSX4 (SS18-SSX4)*, called sometime by the AMP-FPS assay in synovial sarcoma samples, was checked by nested RT-PCR (primers: Fw-SS18 GGACCACCACAGCCACCCCA, Rev-SSX ATGTTTCCCCCTTTTGGGTC; Rev-SSX4 GTCTTGTTAATCTTCTCCAAGG) and Sanger sequencing on a single index case.

For second level bioinformatic analyses of HC library raw data, Arriba, STAR-Fusion and Pizzly ([@B16]--[@B18]), administered through a command line interface, were employed for fusion calling using default settings.

Results {#s3}
=======

NGS-based Identification of Fusion Transcripts: Panel Comparison
----------------------------------------------------------------

As a first step toward the assessment of suitability of NGS-based approaches for the detection of pathognomonic fusions in sarcomas, performance and ease-of-use (library preparation complexity, hands-on time, user-friendly dedicated bioinformatic analysis tool) of three different NGS fusion panels were evaluated on a set of sarcoma samples previously characterized by either FISH or RT-qPCR for gene fusions ([Table 1](#T1){ref-type="table"}). Twenty-six samples were analyzed with a hybrid capture-based panel (HC) (Illumina TS-Fusion). Twenty samples were analyzed with an anchored multiplex PCR panel (Archer AMP-FPS), 19 of which investigated also with the Illumina TS-Fusion. In addition, 9 samples were profiled with a more comprehensive HC panel (Illumina TS-PanCancer).

###### 

NGS fusion profiling: panel comparison.

  **Nr**   **Diagnosis**                                     **Pre-detected genetic abnormality**   **Primary detection method**   **Histotype-specific fusion detected by the indicated NGS approach**   **Other passing filters fusions (assay detecting the additional fusion)**                      
  -------- ------------------------------------------------- -------------------------------------- ------------------------------ ---------------------------------------------------------------------- --------------------------------------------------------------------------- ------------------ ---------------------------------------------
                                                                                                                                   **AMP-FPS**                                                            **TS-Fusion**                                                               **TS-PanCancer**   
  1        Dermatofibrosarcoma Protuberans                   *PDGFB*                                FISH                           *COL1A1-PDGFB^*IL*^*                                                   *COL1A1-PDGFB*                                                              *COL1A1-PDGFB*     NFD
  2        Ewing Sarcoma                                     *EWSR1*                                FISH                           *EWSR1-FLI1^*IL*^*                                                     *EWSR1-FLI1*                                                                *EWSR1-FLI1*       NFD
  3        Infantile Fibrosarcoma                            *ETV6*                                 FISH                           *ETV6-NTRK3^*IL*^*                                                     *ETV6-NTRK3*                                                                *ETV6-NTRK3*       NFD
  4        Synovial Sarcoma                                  *SS18-SSX1*                            RT-qPCR                        *SS18-SSX1^*IL*^*                                                      *SS18-SSX1*                                                                 *SS18-SSX1*        *SS18-SSX4* (AMP-FPS^IL^)
  5        Synovial Sarcoma                                  *SS18*                                 FISH                           *SS18-SSX2^*IL*^*                                                      *SS18-SSX2*                                                                 *SS18-SSX2*        *SS18-SSX4* (AMP-FPS^IL^)
  6        Myoepithelioma (soft tissue)                      *EWSR1*                                FISH                           *EWSR1-ATF1^*IL*^*                                                     *EWSR1-ATF1*                                                                NFD                *ATF1-EWSR1* (TS-Fusion,TS-PanCancer)
  7        Extraskeletal Myxoid Chondrosarcoma               *EWSR1-NR4A3*                          RT-qPCR                        *EWSR1-NR4A3^*IL*^*                                                    NFD                                                                         NFD                NFD
  8        Clear Cell sarcoma                                *EWSR1*                                FISH                           *EWSR1-ATF1^*T,\ IL*^*                                                 NFD                                                                         nd                 NFD
  9        Ewing Sarcoma                                     *EWSR1-FLI1*                           RT-qPCR                        *EWSR1-FLI1^*T,\ IL*^*                                                 *EWSR1-FLI1*                                                                nd                 NFD
  10       Ewing Sarcoma                                     *EWSR1-FLI1*                           RT-qPCR                        *EWSR1-FLI1^*T,\ IL*^*                                                 *EWSR1-FLI1*                                                                nd                 NFD
  11       Ewing Sarcoma                                     *EWSR1-ERG*                            RT-qPCR                        *EWSR1-ERG^*T,\ IL*^*                                                  *EWSR1-ERG*                                                                 nd                 *EWSR1-ERG-EWSR1* (AMP-FPS^IL^)
  12       Extraskeletal Myxoid Chondrosarcoma               *EWSR1-NR4A3*                          RT-qPCR                        *EWSR1-NR4A3^*T*^*                                                     *EWSR1-NR4A3*                                                               nd                 NFD
  13       Myxoid Liposarcoma                                *FUS-DDIT3*                            RT-qPCR                        *FUS-DDIT3^*IL*^*                                                      *FUS-DDIT3*                                                                 nd                 NFD
  14       Myxoid Liposarcoma                                *FUS-DDIT3*                            RT-qPCR                        *FUS-DDIT3^*T,\ IL*^*                                                  *FUS-DDIT3*                                                                 nd                 *DDIT3-FUS* (TS-Fusion)
  15       Myxoid Liposarcoma                                *FUS-DDIT3*                            RT-qPCR                        *FUS-DDIT3^*T,\ IL*^*                                                  *FUS-DDIT3*                                                                 nd                 *FUS-DDIT3-DLG2* (AMP-FPS^IL^)
  16       Synovial Sarcoma                                  *SS18-SSX1*                            RT-qPCR                        *SS18-SSX1^*IL*^*                                                      *SS18-SSX1*                                                                 nd                 *SS18-SSX4-SS18; SS18-SSX4* (AMP-FPS^IL^)
  17       Synovial Sarcoma                                  *SS18*                                 FISH                           *SS18-SSX1^*IL*^*                                                      *SS18-SSX1*                                                                 nd                 NFD
  18       Synovial Sarcoma                                  *SS18-SSX1*                            RT-qPCR                        *SS18-SSX1^*IL*^*                                                      *SS18-SSX1*                                                                 nd                 *SS18-SSX4* (AMP-FPS^IL^)
  19       Synovial Sarcoma                                  *SS18-SSX1*                            RT-qPCR                        *SS18-SSX1^*T,\ IL*^*                                                  *SS18-SSX1*                                                                 nd                 *SS18-SSX1/4-SS18; SS18-SSX4* (AMP-FPS^IL^)
  20       Myxoid Liposarcoma                                *DDIT3*                                FISH                           *FUS-DDIT3^*IL*^*                                                      nd                                                                          *FUS-DDIT3*        *DDIT3-FUS* (TS-PanCancer)
  21       Myxoid Liposarcoma                                *DDIT3*                                FISH                           nd                                                                     FUS-DDIT3                                                                   NFD                NFD
  22       Synovial Sarcoma                                  *SS18*                                 FISH                           nd                                                                     *SS18-SSX1*                                                                 nd                 NFD
  23       Synovial Sarcoma                                  *SS18*                                 FISH                           nd                                                                     *SS18-SSX1*                                                                 nd                 NFD
  24       Myxoid Fibrosarcoma                               *FUS*                                  FISH                           nd                                                                     *FUS-CREB3L2*                                                               nd                 NFD
  25       Myxoid Liposarcoma                                *FUS-DDIT3*                            RT-qPCR                        nd                                                                     *FUS-DDIT3*                                                                 nd                 *DDIT3-FUS* (TS-Fusion)
  26       Myxoid Liposarcoma                                *DDIT3*                                FISH                           nd                                                                     NFD                                                                         nd                 NFD
  27       Undifferentiated Round Cell, Ewing-Like Sarcoma   *CIC*                                  FISH                           nd                                                                     NFD                                                                         nd                 NFD

*NFD, no histotype-specific fusion detected; nd, not done; FISH, fluorescent in situ hybridization; RT-qPCR, reverse transcriptase- quantitative PCR; Sequencing platform used: T, Thermo platform; IL, Illumina platform*.

All three targeted RNA-sequencing panels permit the identification of common and known fusions involved in sarcomas, but also the discovery of novel fusions. The AMP-FPS panel targets a limited set of genes (26 target genes) that are commonly involved in sarcoma-associated fusions. This AMP-FPS panel employs unidirectional gene-specific primers to detect fusion transcripts involving target genes. In addition, molecular barcodes are included to enable single molecule counting, de-duplication and error correction, thus allowing quantitative analysis and confident mutation calling.

In HC-based panels the transcripts of interest are enriched by hybridization and capture with biotinylated probes (507 genes in TS-Fusion, 1385 genes in TS-PanCancer, in both cases including the 26 genes targeted by the AMP-FPS panel).

Raw data obtained with the different panels were then analyzed using the dedicated bioinformatic suite (BaseSpace RNA-Seq Alignment for Illumina HC panels, Archer Analysis platform for the AMP-FPS panel). The AMP-FPS assay correctly identified the pathognomonic fusion in all samples analyzed (20/20), irrespective of the sequencing platform used (Thermo and/or Illumina), demonstrating an excellent sensitivity. The pathognomonic fusion was correctly called in 22/26 samples analyzed with the TS-Fusion HC assay. Of the 9 cases analyzed with the TS-PanCancer HC panel, the dedicated bioinformatic tool identified the diagnostic fusion in 7 cases, in one of these as a reciprocal fusion. To further explore the performance of HC panels, data generated with TS-Fusion and TS-PanCancer panels were re-evaluated with additional algorithms, namely Arriba, STAR-Fusion and Pizzly ([@B16]--[@B18]). Although impractical in a routine diagnostic setting, as they rely on a command line interface, these tools are reported to have high fusion detection rates ([@B16]--[@B18]). With the exception of case \#27, for which no algorithm detected, as high confidence calls, fusions involving the *CIC* gene, apparently rearranged according to FISH, at least one fusion caller was capable of detecting, among others, a fusion transcript involving the target gene in cases previously scored negative with the BaseSpace RNA-Seq Alignment tool, emphasizing the importance of software sensitivity in data analysis ([Supplemental Tables 1](#SM1){ref-type="supplementary-material"}--[3](#SM3){ref-type="supplementary-material"}).

Additional passing filters fusions (in frame and out of frame) were occasionally called beside the pathognomonic one, but the actual biological significance of these alterations is unclear. For instance, beside the canonical fusion involving *SS18* and *SSX1* or *SSX2*, additional fusions involving *SSX4* were called in 5/6 synovial sarcomas analyzed with the AMP-FPS panel. It should be pointed out that the AMP-FPS approach relies on relatively small amplicons. Thus, in the presence of highly homologous genes (e.g., *SSX1, SSX2, SSX4*), this technique may fail to properly distinguish the target ([@B19]). Indeed, a deeper analysis of an index case confirmed the expression of *SS18-SSX1*, suggesting that the alleged *SS18-SSX4* fusion was likely an alignment artifact.

Overall, both AMP-FPS and HC assays demonstrated a good detection capability. The HC assays were definitively more comprehensive and suitable for a research environment. In contrast, the AMP-FPS panel was limited in breath (only 26 target genes), and hence with reduced capacity of discovering new fusions, but definitively provided for a better ease-of-use. In particular, the hands-on-time for library preparation was reduced. Moreover, compared to the BaseSpace RNA-Seq Alignment, the AMP-FPS dedicated bioinformatic analysis tool (Archer Analysis platform) featured a more user-friendly graphical interface with detailed and straightforward information about the fusion (exons involved, in frame/out of frame, confidence of the call) ([Figure 1](#F1){ref-type="fig"}).

![Representative graphical output of Archer Analysis (top) and Illumina BaseSpace RNA-Seq Alignment (bottom) tools. The EWSR1-FLI1 fusion detected in sample \#2 by both AMP-FPS and HC panels is shown.](fonc-10-00489-g0001){#F1}

On the whole, we considered the AMP-FPS assay more suitable for routine diagnostics.

Validation on a Larger Set of Cases of the AMP-FPS Fusion Transcript Assay
--------------------------------------------------------------------------

Based on these results, with a view to translating NGS-based fusion identification in a routine diagnostic setting, we sought to extend the evaluation of the AMP-FPS panel (on either a Thermo or an Illumina sequencing platform) to 123 additional cases ([Table 2](#T2){ref-type="table"}).

###### 

Validation of the AMP-FPS fusion transcript assay.

  **Nr**   **Diagnosis**                                        **Pre-detected genetic abnormality**   **Primary detection method**   **Sequencing platfom**   **Histotype-specific fusion detected**   **Other passing filters fusions**
  -------- ---------------------------------------------------- -------------------------------------- ------------------------------ ------------------------ ---------------------------------------- --------------------------------------------------
  28       Askin Tumor                                          *EWSR1-ERG*                            RT-qPCR                        Illumina                 *EWSR1-ERG*                              *EWSR1-unl-ERG*
  29       Congenital Fibrosarcoma                              *ETV6-NTRK3*                           RT-qPCR                        Illumina                 *ETV6-NTRK3*                             NFD
  30       Dermatofibrosarcoma Protuberans                      *COL1A1-PDGFB*                         FISH                           Thermo                   *COL1A1-PDGFB*                           NFD
  31       Dermatofibrosarcoma Protuberans                      *COL1A1-PDGFB*                         RT-qPCR                        Illumina                 *COL1A1-PDGFB*                           NFD
  32       Ewing Sarcoma                                        *EWSR1*                                FISH                           Thermo                   *EWSR-FLI1*                              NFD
  33       Ewing Sarcoma                                        *EWSR1*                                FISH                           Thermo                   *EWSR-FLI1*                              NFD
  34       Ewing Sarcoma                                        *EWSR1*                                FISH                           Thermo                   *EWSR1-PATZ1*                            NFD
  35       Ewing Sarcoma                                        *EWSR1*                                FISH                           Thermo                   *EWSR-FLI1*                              NFD
  36       Ewing Sarcoma                                        *EWSR1*                                FISH                           Thermo                   *EWSR-FLI1*                              NFD
  37       Ewing Sarcoma                                        *EWSR1-FLI1*                           RT-qPCR                        Illumina                 *EWSR1-FLI1*                             *FXR2-CAMTA1*
  38       Ewing Sarcoma                                        *EWSR1-FLI1*                           RT-qPCR                        Illumina                 *EWSR1-FLI1*                             NFD
  39       Ewing Sarcoma                                        *EWSR1-FLI1*                           RT-qPCR                        Illumina                 *EWSR1-FLI1*                             NFD
  40       Ewing Sarcoma                                        *EWSR1-ERG*                            RT-qPCR                        Illumina                 *EWSR1-ERG*                              *EWSR1-unl-EWSR1-ERG; FUS-ERG; EWSR1-ERG-EWSR1;*
  41       Ewing Sarcoma                                        *EWSR1-FLI1*                           FISH                           Illumina                 *EWSR1-FLI1*                             *EWSR1-FLI1-EWSR1*
  42       Ewing Sarcoma                                        *EWSR1*                                FISH                           Thermo                   *EWSR1-FLI1*                             NFD
  43       Ewing Sarcoma                                        *EWSR1-FLI1*                           RT-qPCR                        Thermo                   *EWSR1-FLI1*                             NFD
  44       Ewing Sarcoma                                        *EWSR1-FLI1*                           RT-qPCR                        Thermo                   *EWSR1-FLI1*                             NFD
  45       Ewing Sarcoma                                        *EWSR1-FLI1*                           RT-qPCR                        Thermo                   *EWSR1-FLI1*                             NFD
  46       Ewing Sarcoma                                        *EWSR1-FLI1*                           RT-qPCR                        Thermo                   *EWSR1-FLI1*                             NFD
  47       Ewing Sarcoma                                        *EWSR1-FLI1*                           RT-qPCR                        Thermo                   *EWSR1-FLI1*                             NFD
  48       Ewing Sarcoma                                        *EWSR1-FLI1*                           RT-qPCR                        Thermo                   *EWSR1-FLI1*                             NFD
  49       Ewing Sarcoma                                        *EWSR1-FLI1*                           RT-qPCR                        Thermo                   *EWSR1-FLI1*                             NFD
  50       Ewing Sarcoma                                        *EWSR1-FLI1*                           RT-qPCR                        Illumina                 *EWSR1-FLI1*                             NFD
  51       Ewing Sarcoma                                        *EWSR1*                                FISH                           Illumina                 *EWSR1-FLI1*                             NFD
  52       Ewing Sarcoma                                        *FUS*                                  FISH                           Thermo                   *FUS-ERG*                                NFD
  53       Ewing-like Sarcoma                                   *BCOR-CCNB3*                           RT-qPCR                        Illumina                 *BCOR-CCNB3*                             NFD
  54       Ewing-like Sarcoma                                   *CIC-DUX4*                             RT-qPCR                        Illumina                 *CIC-DUX4*                               NFD
  55       Extraskeletal Myxoid Chondrosarcoma                  *NR4A3*                                FISH                           Illumina                 *EWSR1-NR4A3*                            NFD
  56       Extraskeletal Myxoid Chondrosarcoma                  *EWSR1*                                FISH                           Illumina                 *EWSR1-NR4A3*                            NFD
  57       Extraskeletal Myxoid Chondrosarcoma                  *EWSR1-NR4A3*                          RT-qPCR                        Illumina                 *EWSR1-NR4A3*                            NFD
  58       Extraskeletal Myxoid Chondrosarcoma                  *TAF15-NR4A3*                          RT-qPCR                        Illumina                 *TAF15-NR4A3*                            NFD
  59       Extraskeletal Myxoid Chondrosarcoma                  *EWSR1-NR4A3*                          RT-qPCR                        Illumina                 *EWSR1-NR4A3*                            NFD
  60       Extraskeletal Myxoid Chondrosarcoma                  *EWSR1-NR4A3*                          RT-qPCR                        Illumina                 *EWSR1-NR4A3*                            NFD
  61       Extraskeletal Myxoid Chondrosarcoma                  *EWSR1-NR4A3*                          RT-qPCR                        Illumina                 *EWSR1-NR4A3*                            NFD
  62       Extraskeletal Myxoid Chondrosarcoma                  *EWSR1-NR4A3*                          RT-qPCR                        Illumina                 *EWSR1-NR4A3*                            NFD
  63       Extraskeletal Myxoid Chondrosarcoma                  *EWSR1-NR4A3*                          RT-qPCR                        Illumina                 *EWSR1-NR4A3*                            NFD
  64       Extraskeletal Myxoid Chondrosarcoma                  *NR4A3*                                FISH                           Illumina                 *EWSR1-NR4A3*                            NFD
  65       Extraskeletal Myxoid Chondrosarcoma                  *EWSR1-NR4A3*                          RT-qPCR                        Illumina                 *EWSR1-NR4A3*                            NFD
  66       Myoepitelial carcinoma (soft tissue)                 *EWSR1*                                FISH                           Illumina                 *EWSR1-ATF1*                             NFD
  67       Myoepithelioma (soft tissue)                         *EWSR1*                                FISH                           Illumina                 *EWSR1-ATF1*                             NFD
  68       Myxoid Liposarcoma                                   *FUS-DDIT3*                            RT-PCR                         Thermo                   *FUS-DDIT3*                              NFD
  69       Myxoid Liposarcoma                                   *FUS-DDIT3*                            RT-qPCR                        Illumina                 *FUS-DDIT3*                              NFD
  70       Myxoid Liposarcoma                                   *FUS-DDIT3*                            FISH                           Thermo                   *FUS-DDIT3*                              NFD
  71       Myxoid Liposarcoma                                   *FUS-DDIT3*                            FISH                           Illumina                 *FUS-DDIT3*                              NFD
  72       Myxoid Liposarcoma                                   *FUS-DDIT3*                            FISH                           Illumina                 *FUS-DDIT3*                              NFD
  73       Nodular Fascitis                                     *USP6*                                 FISH                           Thermo                   *MYH9-USP6*                              NFD
  74       Rhabdomyosarcoma, alveolar                           *PAX3-FOXO1*                           RT-PCR                         Thermo                   *PAX3-FOXO1*                             NFD
  75       Rhabdomyosarcoma, alveolar                           *PAX3-FOXO1*                           RT-PCR                         Thermo                   *PAX3-FOXO1*                             NFD
  76       Rhabdomyosarcoma, alveolar                           *PAX3-FOXO1*                           RT-PCR                         Thermo                   *PAX3-FOXO1*                             NFD
  77       Rhabdomyosarcoma, alveolar                           *PAX3-FOXO1*                           RT-qPCR                        Illumina                 *PAX3-FOXO1*                             NFD
  78       Rhabdomyosarcoma, alveolar                           *PAX3-FOXO1*                           RT-qPCR                        Illumina                 *PAX3-FOXO1*                             NFD
  79       Rhabdomyosarcoma, alveolar                           *PAX3-FOXO1*                           RT-qPCR                        Illumina                 *PAX3-FOXO1*                             NFD
  80       Rhabdomyosarcoma, alveolar                           *PAX3-FOXO1*                           RT-qPCR                        Illumina                 *PAX3-FOXO1*                             NFD
  81       Rhabdomyosarcoma, alveolar                           *PAX3-FOXO1*                           RT-qPCR                        Illumina                 *PAX3 - FOXO1*                           *FOXO1-PAX3*
  82       Rhabdomyosarcoma, alveolar                           *PAX3-FOXO1*                           RT-qPCR                        Illumina                 *PAX3-FOXO1*                             NFD
  83       Rhabdomyosarcoma, splindle cell                      *SRF-NCOA2*                            RT-qPCR                        Illumina                 *SRF- NCOA2*                             NFD
  84       Sarcoma NOS                                          *EWSR1*                                FISH                           Illumina                 *EWSR1-FLI1*                             NFD
  85       Solitary Fibrous Tumor                               *STAT6*                                IHC                            Thermo                   *NAB2-STAT6*                             NFD
  86       Synovial Sarcoma                                     *SS18-SSX2*                            RT-qPCR                        Illumina                 *SS18-SSX2*                              *SS18-SSX4;SS18-SSX1; complex SS18-SSX2 fusions*
  87       Synovial Sarcoma                                     *SS18*                                 FISH                           Illumina                 *SS18-SSX1*                              *SS18-SSX4; SS18-SSX4-SS18*
  88       Synovial Sarcoma                                     *SS18*                                 FISH                           Thermo                   *SS18-SSX1*                              NFD
  89       Synovial Sarcoma                                     *SS18-SSX1*                            RT-qPCR                        Illumina                 *SS18-SSX1*                              NFD
  90       Synovial Sarcoma                                     *SS18-SSX1*                            RT-qPCR                        Thermo                   *SS18-SSX1*                              NFD
  91       Synovial Sarcoma                                     *SS18-SSX1*                            RT-qPCR                        Thermo                   *SS18-SSX1*                              *SS18-SSX2*
  92       Synovial Sarcoma                                     *SS18-SSX1*                            RT-qPCR                        Thermo                   *SS18-SSX1*                              *SS18-SSX4*
  93       Synovial Sarcoma                                     *SS18-SSX1*                            RT-qPCR                        Thermo                   *SS18-SSX1*                              *SS18-SSX4*
  94       Synovial Sarcoma                                     *SS18*                                 FISH                           Illumina                 *SS18-SSX1*                              *SS18-SSX4-SS18*
  95       Synovial Sarcoma                                     *SS18-SSX2*                            RT-qPCR                        Illumina                 *SS18-SSX2*                              NFD
  96       Synovial Sarcoma                                     *SS18*                                 FISH                           Illumina                 *SS18-SSX1*                              *SS18-SSX4*
  97       Synovial Sarcoma                                     *SS18-SSX1*                            RT-qPCR                        Thermo                   *SS18-SSX1*                              *SS18-SSX4*
  98       Clear Cell Sarcoma                                   *EWSR1*                                FISH                           Thermo                   *EWSR1-CREB1*                            NFD
  99       Endometrial Stromal Sarcoma                          *BCOR*                                 FISH                           Thermo                   NFD                                      NFD
  100      Extraskeletal Myxoid Chondrosarcoma                  *NR4A3*                                FISH                           Illumina                 NFD                                      NFD
  101      Myoepithelioma (soft tissue)                         *EWSR1*                                FISH                           Illumina                 NFD                                      NFD
  102      Myxoid Fibrosarcoma                                  *FUS*                                  FISH                           Illumina                 NFD                                      NFD
  103      Myxoid Liposarcoma                                   *DDIT3*                                FISH                           Illumina                 NFD                                      NFD
  104      Nodular Fasciitis                                    *USP6*                                 FISH                           Thermo                   NFD                                      NFD
  105      Rhabdomyosarcoma, alveolar                           *FOXO1*                                FISH                           Thermo                   NFD                                      NFD
  106      Sarcoma NOS                                          *BCOR*                                 FISH                           Thermo                   NFD                                      NFD
  107      Solitary Fibrous Tumor                               *EWSR1*                                FISH                           Illumina                 NFD                                      NFD
  108      Undifferentiated round cell, Ewing-Like Sarcoma      *CIC*                                  FISH                           Illumina                 NFD                                      NFD
  109      Lipoblastoma                                         *PLAG1 neg*                            FISH                           Illumina                 NFD                                      NFD
  110      Myxoid Fibrosarcoma                                  *EWSR1, FUS neg*                       FISH                           Thermo                   NFD                                      NFD
  111      Myxoid Fibrosarcoma                                  *EWSR1, FUS neg*                       FISH                           Thermo                   NFD                                      NFD
  112      Myxoid Fibrosarcoma                                  12q13-15 amp                           FISH                           Thermo                   NFD                                      NFD
  113      Rhabdomyosarcoma, alveolar                           *FOXO1 neg*                            FISH                           Thermo                   NFD                                      NFD
  114      Rhabdomyosarcoma, embryonal                          *FOXO1 neg*                            FISH                           Illumina                 NFD                                      NFD
  115      Rhabdomyosarcoma, embryonal                          *FOXO1 neg*                            FISH                           Illumina                 NFD                                      NFD
  116      Rhabdomyosarcoma, embryonal                          *FOXO1 neg*                            FISH                           Illumina                 NFD                                      NFD
  117      Sarcoma NOS                                          *EWSR1 neg*                            FISH                           Illumina                 *CIC-DUX4*                               NFD
  118      Small Round Cell Tumor                               *EWSR1, BCOR, FUS, CIC neg*            FISH                           Thermo                   NFD                                      NFD
  119      Undifferentiated Sarcoma                             *EWSR1 neg*                            FISH                           Illumina                 *CIC-DUX4*                               NFD
  120      Undifferentiated Sarcoma                             12q13-15 amp                           FISH                           Thermo                   NFD                                      NFD
  121      Undifferentiated Sarcoma                             12q13-15 amp                           FISH                           Thermo                   NFD                                      *HMGA2-LGR5*
  122      Biphenotypic Sinonasal Sarcoma                       nd                                     nd                             Thermo                   *PAX3-MAML3^§^*                          NFD
  123      Biphenotypic Sinonasal Sarcoma                       nd                                     nd                             Thermo                   *PAX3-MAML3^§^*                          NFD
  124      Biphenotypic Sinonasal Sarcoma                       nd                                     nd                             Thermo                   *PAX3-MAML3^§^*                          NFD
  125      Dermatofibrosarcoma Protuberans                      nd                                     nd                             Thermo                   *COL1A1-PDGFB*                           NFD
  126      Endometrial Stromal Sarcoma                          nd                                     nd                             Thermo                   *YWHAE-NUTM2B*                           NFD
  127      Gastrointestinal Neuroectodermal Tumor               nd                                     nd                             Thermo                   *EWSR1-CREB1*                            *SS18-PTRF*
  128      Inflammatory Myofibroblastic Sarcoma                 nd                                     nd                             Illumina                 *TPM4-ALK*                               NFD
  129      Inflammatory Myofibroblastic Tumor                   nd                                     nd                             Thermo                   *TFG-ROS1*                               NFD
  130      Myoepithelioma (bone)                                nd                                     nd                             Illumina                 *FUS-NFATC2*                             NFD
  131      Myoepithelioma (soft tissue)                         nd                                     nd                             Illumina                 *TRPS1-PLAG1*                            NFD
  132      Sclerosing Epitheliodid Fibrosarcoma                 nd                                     nd                             Illumina                 *EWSR1-CREB3L2*                          NFD
  133      Sclerosing epitheliodid fibrosarcoma (soft tissue)   nd                                     nd                             Illumina                 *FUS-CREB3L2*                            NFD
  134      Solitary Fibrous Tumor                               nd                                     nd                             Thermo                   *NAB2-STAT6*                             NFD
  135      Chondrosarcoma                                       nd                                     nd                             Thermo                   NFD                                      NFD
  136      Endometrial Stromal Sarcoma                          nd                                     nd                             Thermo                   NFD                                      NFD
  137      Epithelioid Angiosarcoma                             nd                                     nd                             Illumina                 NFD                                      NFD
  138      Follicular Dendritic Cell Sarcoma                    nd                                     nd                             Thermo                   NFD                                      NFD
  139      Leiomyosarcoma                                       nd                                     nd                             Illumina                 NFD                                      NFD
  140      Leiomyosarcoma                                       nd                                     nd                             Thermo                   NFD                                      NFD
  141      Myoepithelioma (bone)                                nd                                     nd                             Illumina                 NFD                                      NFD
  142      Myxoid Fibrosarcoma                                  nd                                     nd                             Thermo                   NFD                                      NFD
  143      Myxoinflammatory Fibroblastic Sarcoma                nd                                     nd                             Illumina                 NFD                                      NFD
  144      Osteosarcoma                                         nd                                     nd                             Illumina                 NFD                                      NFD
  145      Osteosarcoma                                         nd                                     nd                             Illumina                 NFD                                      NFD
  146      Pleomophic Sarcoma                                   nd                                     nd                             Thermo                   NFD                                      NFD
  147      Pleomophic Sarcoma                                   nd                                     nd                             Thermo                   NFD                                      NFD
  148      Pleomophic Sarcoma                                   nd                                     nd                             Thermo                   NFD                                      NFD
  149      Sarcoma NOS HG Myxoid                                nd                                     FISH                           Thermo                   NFD                                      NFD
  150      Undifferentiated Sarcoma                             nd                                     nd                             Illumina                 NFD                                      NFD

*NFD, no histotype-specific fusion detected; nd, not done; amp, amplification; neg, negative; RT-PCR, reverse transcriptase-PCR; FISH, fluorescent in situ hybridization; RT-qPCR, reverse transcriptase-quantitative PCR; IHC, immunohistochemistry; unl, unaligned sequence. PAX3-MAML3§: fusion detected with a PAX3-customized AMP-FPS Panel. This sample scored negative with the standard AMP-FPS Panel*.

Overall, the AMP-FPS panel confirmed the good performance. Of 81 cases with a pre-detected genetic abnormality suggestive of a fusion event, this NGS assay proved effective in 71, with orthogonal validations (RT-PCR) confirming the NGS result where appropriate (see Material and Methods). In the remaining 10 cases, a gene rearrangement was suggested by FISH. Nevertheless, although samples passed quality filters, the AMP-FPS assay failed to detect a fusion transcript. There are several possible explanations for this discrepancy including inadequate tumor cell fraction or low expression levels of the fusion transcript, chromosome rearrangements not yielding a fusion transcript, unusual breakpoints not covered by the assay or lack of primers covering the target gene. For instance, in two tumors (one endometrial stromal sarcoma and one sarcoma NOS) FISH indicated a rearrangement of the *BCOR* gene with an unknown partner. It is worth noting that the commercial AMP-FPS panel used in this study does not include primers for *BCOR*. Moreover, beside the common *CCNB3* partner (covered by the panel), *BCOR* has been reported to fuse with other genes which are also not targeted by the AMP-FPS assay (e.g., *ZC3H7B, MAML3, CIITA*) ([@B20]--[@B23]). Thus, in the absence of probes for *BCOR* and potential partner genes, the failure of the assay in the 2 *BCOR* rearranged tumors of our series is not surprising. The same holds true for rearrangements involving *NR4A3* in extraskeletal myxoid chondrosarcomas: while the AMP-FPS assay covers the most *NR4A3* common partners (*EWSR1, TAF15, TCF12, TFG*) it lacks probes for both *NR4A3* and uncommon partners ([@B24]), thus scoring negative in the presence of alternative fusions.

The AMP-FPS assay failed to detect any fusion also in 3 cases of biphenotypic sinonasal sarcoma. Although in these cases no prior investigation (FISH or RT-PCR) was performed, this tumor is known to be typified by gene fusions involving the *PAX3* gene ([@B25]). Since the *PAX3* gene is not covered by the commercial AMP-FPS panel, we commissioned a customization of the assay by spiking-in primers to cover *PAX3* fusions. By using this customized AMP-FPS assay we were able to demonstrate and validate that all 3 cases expressed a *PAX3-MAML3* chimeric transcript ([Figure 2](#F2){ref-type="fig"}).

![PAX3-MAML3 fusion detected by the customized AMP-FPS panel in a representative case of biphenotypic sinonasal sarcoma (sample \#123). The top panel shows the output of the Archer Analysis tool. The bottom panel shows the validation of the fusion by RT-PCR sequencing.](fonc-10-00489-g0002){#F2}

Interestingly, a rare EWSR1-PATZ1 fusion was detected by AMP-FPS in one EWSR1 FISH-positive Ewing sarcoma (case \#34). This fusion had been previously described in rare cases of spindled or small round cell sarcomas and it is considered to identify a distinct, Ewing-like entity ([@B26]). Moreover, the NGS profiling allowed the detection of disease-associated fusion transcripts also in a set of cases for which no prior molecular data was available or scored negative for FISH. These included one dermatofibrosarcoma protuberans (*COL1A1-PDGFB*), one endometrial stromal sarcoma (*YWHAE-NUTM2B*, aka *YWHAE-FAM22B*), one gastrointestinal neuroectodermal tumor (*EWSR1-CREB1*), one inflammatory myofibroblastic sarcoma (*TPM4-ALK*), one inflammatory myofibroblastic tumor (*TFG-ROS1*), 2 myoepitheliomas (one *FUS-NFATC2* and one *TRPS1-PLAG1*), 2 sclerosing epithelioid fibrosarcomas (one *EWSR1-CREB3L2* and one *FUS-CREB3L2*) and one solitary fibrous tumor (*NAB2-STAT6*). In addition, 2/5 tumors negative for *EWSR1* rearrangements according to FISH, turned out to express a *CIC-DUX4* fusion, leading to the diagnosis of *CIC-DUX4* fusion-positive undifferentiated round cell sarcoma ([@B27]). In all these cases the identified fusions were confirmed by RT-PCR.

Finally, the series analyzed included also sarcoma variants typically devoid of pathognomonic fusions (e.g., leiomyosarcoma, osteosarcoma). Thus, the negative result of the NGS profiling in these cases may be considered compatible with the pathological diagnosis.

Discussion {#s4}
==========

The expression of fusion transcripts characterizes over a third of sarcomas where it may provide diagnostic, prognostic and predictive information. The cooperative effort described in this work was aimed at assessing feasibility, reliability, and applicability of NGS-based approaches for the detection of pathognomonic fusion transcripts in a routine diagnostic setting.

In line with recent reports ([@B12], [@B19]), our study corroborates the robustness of NGS, and in particular of AMP-FPS profiling, for the detection of clinically relevant fusions in sarcomas. On one hand, our analysis emphasizes the worth of implementing this type of approach in routine diagnostics. On the other hand, it underlines the importance of being aware of the actual detection capability of the panel used (genes covered by the assay) in relation to the specific tumor variant under investigation.

Our study demonstrates also the versatility of certain NGS fusion commercial panels to respond to specific diagnostic needs. In fact, the possibility of further implementing commercially available panels by spiking-in probes for genetic targets not included in the standard version of the assay allows to expand its detection capability. Indeed, beside *PAX3*, due to the recent therapeutic successes of NTRK fusions targeting drugs in solid tumors ([@B7], [@B8]), we are in the process of customizing the AMP-FPS panel by including primers for *NTRK1* and *NTRK2* (currently only *NTRK3* is covered by the AMP-FPS assay).

Importantly, in the presence of a negative result, a re-evaluation of RNA and library quality is mandatory as highly degraded RNA and poor quality libraries may affect the sensitivity of the assay. Nonetheless, we found that apparently low quality samples may still be effective for fusion detection. Indeed, a few cases included in this study (cases \#9, 31, 37, 47, 57, 60, 80, 126), although not fulfilling all quality criteria, nevertheless yielded a correct fusion call. This indicates that this type of assay may work even in suboptimal conditions.

Finally, when reporting the result of this type of NGS analysis, especially if negative, a statement specifying the characteristics and the limits of the assay employed (type of NGS panel, number of target genes, website of the provider for the list of targeted fusions) and the actual performance of the test according to the manufacturer\'s standards (fulfillment of quality parameters) should always be included in the pathology report. It is worth reaffirming that the AMP-FPS assay is designed to target the most common breakpoint regions of the genes covered by the assay. Thus, unusual breakpoints may be source of "false negative" results. Moreover, when dealing with sarcoma variants expressing uncommon fusions, the presence of primers for the target genes should be verified prior to setting up the profiling because the lack of appropriate primers will yield a false negative result. The negativity in the AMP-FPS assay of the two *BCOR* rearranged tumors, included in this series, is instructive in this regard.

In the case of a positive result, beside the genes involved in the fusion, the inclusion in the pathology report of details about the fusion variant detected, including reading frame of the chimeric transcript (in frame/out of frame) and exons involved might be useful. This is of particular importance if the fusion protein is potentially actionable and the retention of specific domains in the chimeric protein is crucial for drug sensitivity, as in the case of NTRK fusions ([@B7]--[@B9]).
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NGS

:   next generation sequencing

FFPE

:   Formalin-Fixed Paraffin-Embedded

FISH

:   fluorescence *in situ* hybridization

RT-PCR

:   reverse transcriptase-PCR

RT-qPCR

:   reverse transcriptase-quantitative PCR

IHC

:   immunohistochemistry

HC

:   hybrid capture-based panel

AMP-FPS

:   Anchored Multiplex PCR FusionPlex Sarcoma panel

TS-Fusion

:   TruSight RNA Fusion panel

TS-PanCancer

:   TruSight RNA PanCancer panel
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